IL301409A - Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) - Google Patents

Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Info

Publication number
IL301409A
IL301409A IL301409A IL30140923A IL301409A IL 301409 A IL301409 A IL 301409A IL 301409 A IL301409 A IL 301409A IL 30140923 A IL30140923 A IL 30140923A IL 301409 A IL301409 A IL 301409A
Authority
IL
Israel
Prior art keywords
cltx
cca
blood
dosing regimen
total daily
Prior art date
Application number
IL301409A
Other languages
English (en)
Hebrew (he)
Original Assignee
Calcilytix Therapeutics Inc
Us Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calcilytix Therapeutics Inc, Us Secretary Department Of Health And Human Services filed Critical Calcilytix Therapeutics Inc
Publication of IL301409A publication Critical patent/IL301409A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL301409A 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) IL301409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US202163159397P 2021-03-10 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (1)

Publication Number Publication Date
IL301409A true IL301409A (en) 2023-05-01

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301409A IL301409A (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Also Published As

Publication number Publication date
EP4213829A1 (en) 2023-07-26
WO2022060987A1 (en) 2022-03-24
MX2023003129A (es) 2023-08-04
US20220087961A1 (en) 2022-03-24
AU2021343475A1 (en) 2023-06-01
TW202227046A (zh) 2022-07-16
KR20230112609A (ko) 2023-07-27
AU2021343475A9 (en) 2024-05-02
CA3192684A1 (en) 2022-03-24
JP2023542932A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
US20220323445A1 (en) Reducing immunogenicity to pegloticase
US20200353057A1 (en) Reducing immunogenicity to pegloticase
US12465631B2 (en) Reducing immunogenicity to pegloticase
AU2013282394B2 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
IL322175A (en) Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
Gaudet et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study
JP2018515460A (ja) 炎症または神経障害性疼痛を処置する方法
IL301910A (en) Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults
US20220409620A1 (en) Reducing immunogenicity to pegloticase
IL275115B2 (en) Bis-choline tetrathiolmolybdate for the treatment of Wilson's disease
Bacchetta et al. X-linked hypophosphatemia and burosumab: practical clinical points from the French experience
US20220087961A1 (en) Treatment methods of triphenyl calcilytic compounds
Clayton et al. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants
IL300285A (en) Formulations of triphenyl calcilytic compounds
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
TW202506101A (zh) 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療
Springer Publishing Company Adult-Gerontology Acute Care Nurse Practitioner Certification Practice Q&A: 700 Practice Questions Based on the Latest Exam Blueprint
WO2025235883A1 (en) Acoramidis for use in the treatment of renal dysfunction
Sato et al. Hypomagnesemia Causing Convulsions in a Patient Taking a Proton Pump Inhibitor: A Case Report
WO2026078027A1 (en) Dosage regimens for camlipixant in treating chronic cough
Home Benazepril Oral Benazepril is an angiotensin-converting enzyme (ACE) inhibitor.[Brand Name: Lotensin Classes: Angiotensin-Converting Enzyme Inhibitors (24: 32.04),(24: 08.44. 04)
Lézard FDA Approves Daiichi Sankyo's TURALIOtm (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
Arora Janssen-Cilag Taiwan, Johnson & Johnson